Treatment.com AI Inc (CSE: TRUE) Revolutionizing Healthcare Through AI and Education

0
62

The global artificial intelligence (AI) in healthcare market size was estimated at USD 15.1 billion in 2022 and it is expected to surpass around USD 187.95 billion by 2030, growing at a CAGR of 37% during the forecast period 2022 to 2030. North America AI in healthcare market was valued at USD 6.8 billion in 2022. This suggests that companies with a viable healthcare-related AI product could benefit from the growing use of AI in healthcare.

Vancouver-based Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) is making significant strides in the healthcare technology sector, recently announcing the appointment of Richard Atkins as Chief Operating Officer. Atkins brings over 30 years of international experience in health-tech and software, significantly enhancing the company’s leadership as it expands its innovative AI-driven solutions.

Treatment.com AI is thrilled to continue its growth with the renewal of a key contract with one of the leading US medical schools for its Medical Education Suite (MES). This renewal validates the effectiveness of the MES, which reduces time and costs associated with medical exams and administrative tasks, streamlining processes for medical and nursing schools across the US and internationally. The suite, supported by the proprietary Global Library of Medicine (GLM), ensures high-quality clinical information is accessible, enhancing the education of healthcare professionals.

Adding to its robust offerings, Treatment.com AI has introduced two innovative solutions aimed at the next generation of healthcare providers: AI Patient and AI Doctor in a Pocket. These tools are set to launch in the second half of 2024 as part of the MES. AI Patient will aid students in preparing for medical exams like MCQs and OSCEs by providing a library of test cases. Meanwhile, AI Doctor in a Pocket offers a mobile-friendly, AI-powered clinical decision support tool that can be utilized in clinical settings, ensuring that students and healthcare professionals have access to reliable guidance when it matters most.

These initiatives are part of a broader strategy to support the educational needs of 300 medical schools and 900 nursing schools in the US, with ongoing discussions to expand to schools in the UK and Canada. The comprehensive support provided by the MES and the newly announced SaaS solutions underscore Treatment.com AI’s commitment to enhancing medical education and healthcare practice globally.

Dr. Essam Hamza, CEO of Treatment.com AI, expressed his excitement about these developments, emphasizing their focus on supporting students through their education and into their medical practices with trusted, innovative tools. “Our goal is for students to be supported and excel during their medical education, and to continue utilizing the same trusted platform as they move into practice,” said Dr. Hamza.

The company’s commitment to innovation and education is further supported by strategic marketing and advertising collaborations, including a renewed partnership with Sunburst Data Corp. and a new engagement with 45 Degrees, Inc., to enhance its visibility and outreach.

As Treatment.com AI continues to advance its mission of utilizing AI for good, the company remains a compelling option for investors and traders interested in the intersection of technology and healthcare. The ongoing expansions, strategic appointments, and innovative product launches position Treatment.com AI as a leader in revolutionizing healthcare through technology.

Other Health Care AI Stocks to keep an eye out include HEALWELL AI Inc (TSX: AIDX), HEALWELL AI Inc (OTCQX: HWAIF), Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc. (NASDAQ: GEHC), VERSES AI Inc (OTCMKTS: VRSSF), VERSES AI Inc (CBOE: VERS)

LEAVE A REPLY

Please enter your comment!
Please enter your name here